JAZZ Q2 2024 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$12B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.0B+6.9% YoY

Gross Profit

$914M89.3% margin

Operating Income

$199M19.5% margin

Net Income

$169M16.5% margin

EPS (Diluted)

$2.49

QoQ Revenue Growth

+13.5%

Cash Flow

Operating Cash Flow

$331M

Free Cash Flow

$324M

Stock-Based Comp.

$57M

Balance Sheet

Total Assets

$11.4B

Total Liabilities

$7.6B

Stockholders' Equity

$3.8B

Cash & Equivalents

$1.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.0B	$957M	+6.9%
Gross Profit	$914M	$860M	+6.3%
Operating Income	$199M	$158M	+26.5%
Net Income	$169M	$104M	+61.4%

Revenue Segments

Xywav

$368M36%

Epidiolex/Epidyolex

$247M24%

Rylaze/Enrylaze

$108M11%

Zepzelca

$81M8%

Xyrem

$62M6%

High Sodium AG Oxybate Product Royalty Revenue

$54M5%

Defitelio/Defibrotide

$45M4%

Vyxeos

$43M4%

Sativex

$6M1%

Other Royalty And Contract Revenues

$6M1%

Other Products

$3M0%

Geographic Segments

UNITED STATES

$925M90%

Europe

$82M8%

Other Countries

$17M2%